Skip to search formSkip to main contentSkip to account menu

Farnesyl Transferase Inhibitor

Known as: Farnesyl Transferase Inhibitors, Farnesyltransferase Inhibitors, FTI 
Any substance that inhibits protein farnesyltransferase, an enzyme that catalyzes the transfer of a farnesyl moiety from farnesyl pyrophosphate to a… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation
Zoledronic acid (ZOL) has proved activity in bone metastases from prostate cancer through inhibition of mevalonate pathway and of… 
Highly Cited
2006
Highly Cited
2006
HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway.
Resistance of glioblastoma multiforme to radiotherapy poses a major clinical challenge. Farnesyltransferase inhibitors (FTI… 
2006
2006
Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.
If you had told me 5 years ago that I would be writing a commentary on an exciting report on the prospects of incorporating the… 
Review
2005
Review
2005
Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis.
Protein farnesyl transferase inhibitors (PFTIs) have been developed as oncology therapeutics but recent studies have supported… 
2005
2005
Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS‐to‐MAP kinase signalling in multiple myeloma cells
The high incidence of activating RAS mutations, coupled with accumulating evidence linking RAS to multiple myeloma (MM… 
Review
2003
Review
2003
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clinical trials… 
Highly Cited
2001
Highly Cited
2001
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many… 
Highly Cited
1999
Highly Cited
1999
Integrin-dependent Leukocyte Adhesion Involves Geranylgeranylated Protein(s)*
Integrin-dependent leukocyte adhesion is modulated by alterations in receptor affinity or by post-receptor events. Pretreatment… 
Review
1999
Review
1999
Concepts in Ras-directed therapy.
Ras proteins are key transducers of growth signals regulated by cell surface receptors. They are anchored to the inner surface of… 
Highly Cited
1996
Highly Cited
1996
Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Cysteine farnesylation of the ras oncogene product Ras is required for its transforming activity and is catalyzed by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)